Dr Stone presents, at a press conference at ASH 2015, results from an international prospective randomised P-controlled double-blind trial.

The findings shows the multi-kinase inhibitor midostaurin prolongs survival, compared with placebo in combination with daunorubicin/cytarabine induction, high-dose C consolidation, and as maintenance therapy in newly diagnosed acute myeloid leukaemia patients with FLT3 Mutations.

Read the news story and watch the video interview for more information.